Clinical Trial

Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Inhaler in patients with bronchial asthma.
Trial Details
NCT Number NCT07324707
Lead Sponsor Anhui Palo Alto Pharmaceuticals, Inc.
Conditions Bronchial Asthma
Enrollment 30 participants
Start Date 2025-10-15
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-07